Wen C, Fraser T, Li M, Turner S W, Whitworth J A
Department of Medicine, The St George Hospital, University of New South Wales, Sydney, Australia.
J Hypertens. 1999 Dec;17(12 Pt 1):1715-23. doi: 10.1097/00004872-199917120-00008.
To investigate the roles of cardiac output and systemic and regional resistances in corticotropin (ACTH)-induced hypertension in the rat
This study consisted of three series of experiments with eight groups of male Sprague-Dawley rats (n = 132). Series 1 comprised groups 1-4, where group 1 = sham (0.9% NaCl, subcutaneous (s.c.) injection); group 2 = ACTH (0.5 mg/kg per day, s.c.); group 3 = atenolol + sham; group 4 = atenolol + ACTH treatments. Series 2 comprised groups 5 and 6, where group 5 = minoxidil + sham and group 6 = minoxidil + ACTH treatments. Series 3 comprised groups 7 and 8, where group 7 = ramipril + sham and group 8 = ramipril + ACTH treatments. Systolic blood pressure, water and food intakes, urine volume, and body weight were measured every second day. After 10 days of treatment, mean arterial blood pressure was measured by intra-arterial cannulation, and cardiac output (CO), and renal, mesenteric and hindquarter blood flows (RBF, MBF and HBF) determined using transonic small animal flowmeters.
ACTH treatment increased blood pressure (P < 0.001) with a rise in CO (P < 0.01) and renal vascular resistance (RVR, P < 0.05), but did not affect total peripheral resistance (TPR). Atenolol blocked the rise in CO without affecting the rise in blood pressure produced by ACTH treatment Minoxidil lowered TPR, but did not prevent the rise in blood pressure or renal vascular resistance. Ramipril blunted the rise in RVR and blood pressure without significantly affecting TPR.
Neither preventing rise in CO nor lowering TPR altered the ACTH-induced rise in blood pressure in the rat However, both the hypertension and rise in RVR were prevented by ramipril. These data suggest that increase in RVR may play a role in the pathogenesis of ACTH-induced hypertension in the rat.
研究心输出量以及全身和局部阻力在促肾上腺皮质激素(ACTH)诱导的大鼠高血压中的作用
本研究包括三组系列实验,每组有八组雄性Sprague-Dawley大鼠(n = 132)。系列1包括第1 - 4组,其中第1组 = 假手术组(皮下注射0.9%氯化钠);第2组 = ACTH组(每天0.5 mg/kg,皮下注射);第3组 = 阿替洛尔 + 假手术组;第4组 = 阿替洛尔 + ACTH组。系列2包括第5和6组,其中第5组 = 米诺地尔 + 假手术组,第6组 = 米诺地尔 + ACTH组。系列3包括第7和8组,其中第7组 = 雷米普利 + 假手术组,第8组 = 雷米普利 + ACTH组。每隔一天测量收缩压、水和食物摄入量、尿量及体重。治疗10天后,通过动脉插管测量平均动脉血压,并使用跨音速小动物流量计测定心输出量(CO)以及肾、肠系膜和后肢血流量(RBF、MBF和HBF)。
ACTH治疗使血压升高(P < 0.001),同时CO升高(P < 0.01)和肾血管阻力(RVR,P < 0.05)升高,但不影响总外周阻力(TPR)。阿替洛尔可阻止CO升高,但不影响ACTH治疗引起的血压升高。米诺地尔降低TPR,但不能阻止血压升高或肾血管阻力升高。雷米普利可减弱RVR和血压升高,而对TPR无显著影响。
阻止CO升高或降低TPR均不能改变ACTH诱导的大鼠血压升高。然而,雷米普利可预防高血压和RVR升高。这些数据表明,RVR升高可能在ACTH诱导的大鼠高血压发病机制中起作用。